KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

First-line PARP inhibitor maintenance treatment in ovarian carcinoma for older adult women: a review of the current literature.

Maria Masvidal Hernandez, Sara Cros Costa, Carmen Salvador Coloma, Alicia Quilez Cutillas, Maria-Pilar Barretina-Ginesta, Almudena Cotes Sanchís

Clin Transl Oncol 27(2) 417-424

PMID39030437
PMCID-
DOI10.1007/s12094-024-03609-y
发表日期2024-07-19
摘要

摘要

Ovarian cancer (OC) is the leading cause of death in women with gynecological cancers. Its diagnosis is more likely in advanced ages, with the older population being the most seen in consultations. Poly(ADP-ribose) inhibitors (PARPi) have changed OC clinical practice and evolution, showing great benefit. However, there is a lack of evidence of PARPi in elderly population that can impact the therapeutic decision and the safety/efficacy. It is necessary to avoid age as limiting factor in PARPis prescription. We conducted a review of the most relevant randomized phase III trials of maintenance PARPi after first-line treatment of advanced OC. We observed the lack of a single criterion for considering older patients, varying among trials. There is a benefit of PARPis in different populations. However, PARPi effect on quality of life is not reported, something of great relevance considering their vulnerability. Measures are needed to benefit older patients to better adapt PARPi treatment.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。